​

Bioventus (BVS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BVS Stock Forecast

Bioventus stock forecast is as follows: an average price target of $12.00 (represents a 12.46% upside from BVS’s last price of $10.67) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

BVS Price Target

The average price target for Bioventus (BVS) is $12.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 12.46% upside from BVS's last price of $10.67.

BVS Analyst Ratings

Buy

According to 4 Wall Street analysts, Bioventus's rating consensus is 'Buy'. The analyst rating breakdown for BVS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Bioventus Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 01, 2024Caitlin CroninCanaccord Genuity$12.00$11.791.78%12.46%
Aug 07, 2024Chase KnickerbockerCraig-Hallum$12.00$8.2545.45%12.46%
May 07, 2024William PlovanicCanaccord Genuity$8.00$5.1256.25%-25.02%
Mar 13, 2024Alex NowakCraig-Hallum$9.00$5.2970.13%-15.65%
Nov 30, 2022Goldman Sachs$2.50$1.9130.89%-76.57%

The latest Bioventus stock forecast, released on Oct 01, 2024 by Caitlin Cronin from Canaccord Genuity, set a price target of $12.00, which represents a 1.78% increase from the stock price at the time of the forecast ($11.79), and a 12.46% increase from BVS last price ($10.67).

Bioventus Price Target by Period

1M3M12M
# Anlaysts-14
Avg Price Target-$12.00$10.25
Last Closing Price$10.67$10.67$10.67
Upside/Downside-100.00%12.46%-3.94%

In the current month, the average price target of Bioventus stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bioventus's last price of $10.67. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2024RBC CapitalOutperformUpgrade
Oct 01, 2024Canaccord GenuityBuyBuyHold
Sep 27, 2024Craig-HallumBuyBuyHold
Aug 07, 2024Craig-HallumBuyBuyHold
May 07, 2024Canaccord GenuityBuyBuyHold
Dec 07, 2023Canaccord GenuityBuyUpgrade
Nov 30, 2022Goldman SachsNeutralNeutralHold
Nov 22, 2022Craig-HallumHoldDowngrade

Bioventus's last stock rating was published by RBC Capital on Dec 02, 2024. The company Upgrade its BVS rating from "null" to "Outperform".

Bioventus Financial Forecast

Bioventus Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
Revenue--------$135.42M-$137.07M$119.06M$125.83M$137.07M$140.33M$117.29M$130.41M$108.89M$109.82M$81.78M$98.59M
Avg Forecast$157.60M$149.90M$159.02M$138.67M$144.83M$133.24M$137.60M$118.37M$123.96M$119.00M$129.23M$116.57M$132.59M$141.59M$138.33M$117.69M$130.23M$102.39M$100.97M$76.54M$98.08M
High Forecast$157.95M$150.24M$159.38M$139.13M$145.15M$133.94M$137.91M$118.37M$124.24M$119.27M$129.52M$116.83M$132.89M$141.59M$138.33M$117.69M$130.23M$102.39M$100.97M$76.54M$98.08M
Low Forecast$157.26M$149.58M$158.68M$138.20M$144.52M$132.53M$137.30M$118.37M$123.69M$118.74M$128.96M$116.32M$132.31M$141.59M$138.33M$117.69M$130.23M$102.39M$100.97M$76.54M$98.08M
# Analysts111221112111111111111
Surprise %--------1.09%-1.06%1.02%0.95%0.97%1.01%1.00%1.00%1.06%1.09%1.07%1.01%

Bioventus's average Quarter revenue forecast for Mar 24 based on 1 analysts is $118.37M, with a low forecast of $118.37M, and a high forecast of $118.37M. BVS's average Quarter revenue forecast represents a -12.59% decrease compared to the company's last Quarter revenue of $135.42M (Dec 23).

Bioventus EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts111221112111111111111
EBITDA--------$52.56M-$55.23M$82.85M$-4.29M$35.58M$11.64M$-7.28M$9.56M$7.92M$5.07M$32.05M$13.18M
Avg Forecast$6.31M$6.00M$6.36M$5.55M$5.80M$5.33M$5.51M$4.74M$4.96M$4.76M$5.17M$4.66M$5.31M$19.25M$18.80M$16.00M$17.70M$13.92M$13.72M$10.40M$13.33M
High Forecast$6.32M$6.01M$6.38M$5.57M$5.81M$5.36M$5.52M$4.74M$4.97M$4.77M$5.18M$4.68M$5.32M$19.25M$18.80M$16.00M$17.70M$13.92M$13.72M$10.40M$13.33M
Low Forecast$6.29M$5.99M$6.35M$5.53M$5.78M$5.30M$5.49M$4.74M$4.95M$4.75M$5.16M$4.65M$5.29M$19.25M$18.80M$16.00M$17.70M$13.92M$13.72M$10.40M$13.33M
Surprise %--------10.60%-10.68%17.76%-0.81%1.85%0.62%-0.46%0.54%0.57%0.37%3.08%0.99%

1 analysts predict BVS's average Quarter EBITDA for Mar 24 to be $4.74M, with a high of $4.74M and a low of $4.74M. This is -90.99% lower than Bioventus's previous annual EBITDA (Dec 23) of $52.56M.

Bioventus Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts111221112111111111111
Net Income--------$-6.10M-$-3.68M$-100.02M$-44.87M$3.17M$-8.01M$-14.81M$-1.89M$-1.07M$-4.13M$24.94M$2.78M
Avg Forecast$14.77M$12.19M$15.31M$4.21M$5.39M$1.06M$4.39M$-4.35M$1.25M$-1.31M$-217.51K$-9.79M$3.13M$7.87M$9.98M$3.05M$11.29M$9.00M$8.75M$145.88M$14.73M
High Forecast$14.82M$12.23M$15.35M$5.18M$5.41M$1.06M$4.40M$-4.34M$1.25M$-1.30M$-216.90K$-9.76M$3.14M$7.87M$9.98M$3.05M$11.29M$9.00M$8.75M$175.05M$14.73M
Low Forecast$14.73M$12.16M$15.26M$3.24M$5.38M$1.06M$4.38M$-4.36M$1.25M$-1.31M$-218.14K$-9.82M$3.13M$7.87M$9.98M$3.05M$11.29M$9.00M$8.75M$116.70M$14.73M
Surprise %---------4.88%-16.92%10.22%-14.32%0.40%-0.80%-4.85%-0.17%-0.12%-0.47%0.17%0.19%

Bioventus's average Quarter net income forecast for Dec 22 is $3.13M, with a range of $3.13M to $3.14M. BVS's average Quarter net income forecast represents a -1.29% decrease compared to the company's last Quarter net income of $3.17M (Sep 22).

Bioventus SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts111221112111111111111
SG&A--------$78.36M-$74.84M$80.86M$77.67M$84.33M$89.62M$86.12M$80.88M$69.64M$69.05M$34.69M$61.97M
Avg Forecast$95.11M$90.46M$95.96M$83.68M$87.40M$80.40M$83.04M$71.43M$74.80M$71.81M$77.99M$70.34M$80.01M$84.67M$82.72M$70.38M$77.88M$61.23M$60.38M$45.77M$58.65M
High Forecast$95.32M$90.66M$96.18M$83.96M$87.60M$80.83M$83.22M$71.43M$74.97M$71.97M$78.16M$70.50M$80.19M$84.67M$82.72M$70.38M$77.88M$61.23M$60.38M$45.77M$58.65M
Low Forecast$94.90M$90.27M$95.76M$83.40M$87.21M$79.98M$82.86M$71.43M$74.64M$71.66M$77.82M$70.19M$79.84M$84.67M$82.72M$70.38M$77.88M$61.23M$60.38M$45.77M$58.65M
Surprise %--------1.05%-0.96%1.15%0.97%1.00%1.08%1.22%1.04%1.14%1.14%0.76%1.06%

Bioventus's average Quarter SG&A projection for Mar 24 is $71.43M, based on 1 Wall Street analysts, with a range of $71.43M to $71.43M. The forecast indicates a -8.84% fall compared to BVS last annual SG&A of $78.36M (Dec 23).

Bioventus EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts111221112111111111111
EPS--------$-0.10-$-0.06$-1.61$-0.72$0.05$-0.13$-0.24$-0.03$-0.03$-0.10$0.60$0.07
Avg Forecast$0.23$0.19$0.23$0.06$0.08$0.02$0.07$-0.07$0.02$-0.02$-0.00$-0.15$0.05$0.12$0.16$0.05$0.18$0.14$0.14$0.28$0.23
High Forecast$0.23$0.19$0.24$0.08$0.08$0.02$0.07$-0.07$0.02$-0.02$-0.00$-0.15$0.05$0.12$0.16$0.05$0.18$0.14$0.14$0.28$0.23
Low Forecast$0.23$0.19$0.23$0.05$0.08$0.02$0.07$-0.07$0.02$-0.02$-0.00$-0.15$0.05$0.12$0.16$0.05$0.18$0.14$0.14$0.28$0.23
Surprise %---------5.05%-17.64%10.73%-14.99%0.42%-0.83%-5.04%-0.20%-0.21%-0.73%2.13%0.30%

According to 1 Wall Street analysts, Bioventus's projected average Quarter EPS for Dec 22 is $0.05, with a low estimate of $0.05 and a high estimate of $0.05. This represents a -6.74% decrease compared to BVS previous annual EPS of $0.05 (Sep 22).

Bioventus Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
RPIDRapid Micro Biosystems$1.06$8.00654.72%Hold
BJDXBluejay Diagnostics$4.38$10.00128.31%Buy
BVSBioventus$11.15$12.007.62%Buy
HSCSHeart Test Laboratories$3.85$3.00-22.08%Buy

BVS Forecast FAQ

Is Bioventus a good buy?

Yes, according to 4 Wall Street analysts, Bioventus (BVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of BVS's total ratings.

What is BVS's price target?

Bioventus (BVS) average price target is $12 with a range of $12 to $12, implying a 12.46% from its last price of $10.67. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Bioventus stock go up soon?

According to Wall Street analysts' prediction for BVS stock, the company can go up by 12.46% (from the last price of $10.67 to the average price target of $12), up by 12.46% based on the highest stock price target, and up by 12.46% based on the lowest stock price target.

Can Bioventus stock reach $20?

BVS's average twelve months analyst stock price target of $12 does not support the claim that Bioventus can reach $20 in the near future.

What are Bioventus's analysts' financial forecasts?

Bioventus's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $534.03M (high $535.37M, low $532.72M), average EBITDA is $21.37M (high $21.42M, low $21.32M), average net income is $6.49M (high $6.53M, low $6.45M), average SG&A $322.27M (high $323.08M, low $321.48M), and average EPS is $0.0994 (high $0.1, low $0.0989). BVS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $605.19M (high $606.7M, low $603.72M), average EBITDA is $24.22M (high $24.28M, low $24.16M), average net income is $46.49M (high $47.58M, low $45.4M), average SG&A $365.21M (high $366.12M, low $364.32M), and average EPS is $0.712 (high $0.729, low $0.696).

Did the BVS's actual financial results beat the analysts' financial forecasts?

Based on Bioventus's last annual report (Dec 2023), the company's revenue was $100K, which missed the average analysts forecast of $488.76M by -99.98%. Apple's EBITDA was $38K, missing the average prediction of $19.56M by -99.81%. The company's net income was $0, missing the average estimation of $-10.062M by -100.00%. Apple's SG&A was $59.4K, missing the average forecast of $294.95M by -99.98%. Lastly, the company's EPS was $0, missing the average prediction of $-0.154 by -100.00%. In terms of the last quarterly report (Dec 2023), Bioventus's revenue was $135.42M, beating the average analysts' forecast of $123.96M by 9.25%. The company's EBITDA was $52.56M, beating the average prediction of $4.96M by 959.53%. Bioventus's net income was $-6.096M, missing the average estimation of $1.25M by -587.90%. The company's SG&A was $78.36M, beating the average forecast of $74.8M by 4.75%. Lastly, the company's EPS was $-0.0966, missing the average prediction of $0.0191 by -604.54%